Fibrosis is not a Static Disease

Fibrosis is the excessive buildup of extracellular matrix (ECM) components, including collagen, in tissues as a response to chronic injury or inflammation. This process leads to tissue scarring and dysfunction. It is not merely an accumulation of ECM products but a dynamic process involving both the production and degradation of these components, resulting in increased collagen levels. In active fibrosis, collagen is highly remodeled and damaged.

How CHPs Address Key Collagen-Related Challenges in Fibrosis Research

CHPs provide researchers with precise, actionable insights into fibrosis progression, helping to enhance early detection, monitor treatment efficacy, and optimize patient outcomes.

Precise Detection & Quantification

CHPs selectively bind to denatured collagen, enabling early and accurate detection of active fibrotic areas.

Real-Time Drug Monitoring

CHPs track tissue responses to therapies, offering a reliable metric for therapeutic impact.

Patient Stratification

CHPs distinguish between active and stable fibrosis, helping optimize treatment matching and trial efficiency.

Optimized Treatment Timing

CHPs provide insights into fibrosis treatability, allowing researchers to time interventions for maximum efficacy.